Teclistamab in Relapsed or Refractory Multiple Myeloma-Reference-Cited by-同舟云学术

Teclistamab in Relapsed or Refractory Multiple Myeloma

Published:2022-08-11 Issue:6 Volume:387 Page:495-505
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Moreau Philippe¹,Garfall Alfred L.¹,van de Donk Niels W.C.J.¹,Nahi Hareth¹,San-Miguel Jesús F.¹,Oriol Albert¹,Nooka Ajay K.¹,Martin Thomas¹,Rosinol Laura¹,Chari Ajai¹,Karlin Lionel¹,Benboubker Lotfi¹,Mateos Maria-Victoria¹,Bahlis Nizar¹,Popat Rakesh¹,Besemer Britta¹,Martínez-López Joaquín¹,Sidana Surbhi¹,Delforge Michel¹,Pei Lixia¹,Trancucci Danielle¹,Verona Raluca¹,Girgis Suzette¹,Lin Shun X.W.¹,Olyslager Yunsi¹,Jaffe Mindy¹,Uhlar Clarissa¹,Stephenson Tara¹,Van Rampelbergh Rian¹,Banerjee Arnob¹,Goldberg Jenna D.¹,Kobos Rachel¹,Krishnan Amrita¹,Usmani Saad Z.¹

Affiliation:

1. From the Hematology Clinic, University Hospital Hôtel-Dieu, Nantes (P.M.), Service d’Hématologie Clinique, Centre Hospitalier Lyon Sud, Pierre-Bénite (L.K.), and Service d’Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, Tours (L.B.) — all in France; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.L.G.), and Janssen Research and Development, Spring House (R.V., S.G., S.X.W.L., C.U., T.S., A.B.) — both in...

Funder

Janssen Research & Development, LLC

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2203478

Reference24 articles.

1. Multiple myeloma: patient outcomes in real‐world practice

2. Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology

3. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

4. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Cited by 475 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision medicine for multiple myeloma: The case for translocation (11;14);Cancer Treatment Reviews;2024-11

2. Teclistamab for relapsed refractory multiple myeloma patients on dialysis;British Journal of Haematology;2024-09-14

3. Bispecific antibodies in the treatment of multiple myeloma;Blood Cancer Journal;2024-09-12

4. Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial;Blood Cancer Journal;2024-09-11

5. ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells;Nature Cancer;2024-09-11